Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) EBITDA Margin (2016 - 2026)

Anika Therapeutics has reported EBITDA Margin over the past 17 years, most recently at 18.26% for Q1 2026.

  • Quarterly EBITDA Margin fell 224.0% to 18.26% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 8.83% through Mar 2026, up 3946.0% year-over-year, with the annual reading at 8.03% for FY2025, 3970.0% up from the prior year.
  • EBITDA Margin was 18.26% for Q1 2026 at Anika Therapeutics, down from 0.89% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 2151.74% in Q4 2023 and troughed at 98.8% in Q3 2024.
  • The 5-year median for EBITDA Margin is 9.3% (2022), against an average of 115.74%.
  • Year-over-year, EBITDA Margin skyrocketed 201346bps in 2023 and then crashed -222673bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 138.28% in 2022, then skyrocketed by 1456bps to 2151.74% in 2023, then plummeted by -103bps to 74.99% in 2024, then soared by 101bps to 0.89% in 2025, then tumbled by -2155bps to 18.26% in 2026.
  • Per Business Quant, the three most recent readings for ANIK's EBITDA Margin are 18.26% (Q1 2026), 0.89% (Q4 2025), and 9.03% (Q3 2025).